tiprankstipranks
Advertisement
Advertisement
Dianthus Therapeutics: Best-in-Class C1s Antibody Claseprubart and Strong Execution Support Outperform Rating
PremiumRatingsDianthus Therapeutics: Best-in-Class C1s Antibody Claseprubart and Strong Execution Support Outperform Rating
2M ago
Bullish View on Dianthus: Claseprubart’s Differentiated Complement Inhibition and Underappreciated Bifunctional Pipeline Drive Buy Rating
Premium
Ratings
Bullish View on Dianthus: Claseprubart’s Differentiated Complement Inhibition and Underappreciated Bifunctional Pipeline Drive Buy Rating
2M ago
Dianthus initiated with an Outperform at Wolfe Research
Premium
The Fly
Dianthus initiated with an Outperform at Wolfe Research
2M ago
Dianthus 7.3M share Secondary priced at $81.00
PremiumThe FlyDianthus 7.3M share Secondary priced at $81.00
3M ago
Dianthus price target raised to $80 from $55 at Wedbush
Premium
The Fly
Dianthus price target raised to $80 from $55 at Wedbush
3M ago
Dianthus price target raised to $132 from $67 at Baird
Premium
The Fly
Dianthus price target raised to $132 from $67 at Baird
3M ago
Dianthus price target raised to $98 from $81 at Jefferies
PremiumThe FlyDianthus price target raised to $98 from $81 at Jefferies
3M ago
Dianthus price target raised to $132 from $67 at Baird
Premium
The Fly
Dianthus price target raised to $132 from $67 at Baird
3M ago
Dianthus a ‘viable takeout target,’ says TD Cowen
Premium
The Fly
Dianthus a ‘viable takeout target,’ says TD Cowen
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100